| Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) (NCT05281406) | Goethe University | 2021-11-12 |
| Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer (NCT05132218) | Peking University Cancer Hospital & Institute | 2021-10-19 |
| Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (NCT04467801) | Jun Zhang, MD, PhD | 2021-09-14 |
| Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor (NCT04932343) | Samsung Medical Center | 2021-06-01 |
| Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (NCT04865250) | University Hospital Heidelberg | 2021-01-07 |
| Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC (NCT04768491) | Peking Union Medical College | 2020-09-01 |
| Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer (NCT03628144) | H. Lee Moffitt Cancer Center and Research Institute | 2020-07-01 |
| Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (NCT04223596) | Fundación GECP | 2020-05-04 |
| A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies (NCT04042558) | Centre Francois Baclesse | 2019-09-26 |
| Phase 2 Study of Dacomitinib in NSCLC (NCT04027647) | National Cancer Centre, Singapore | 2019-09-11 |
| Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (NCT03805841) | Rain Oncology Inc | 2019-03-13 |
| 1st Line Durvalumab in PS 2 NSCLC Patients (NCT03620669) | Swiss Cancer Institute | 2018-12-04 |
| Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors (NCT03647956) | The University of Hong Kong | 2018-10-01 |
| Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study (NCT03594682) | Beijing Chest Hospital | 2018-08-01 |
| Phase I Study of SPH1188-11 in NSCLC (NCT03231475) | Shanghai Pharmaceuticals Holding Co., Ltd | 2017-07-21 |
| Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer (NCT03515252) | Ivy Life Sciences, Co., Ltd | 2005-04-26 |
| Chemoradiotherapy of NSCLC Stage IIIB (NCT00198432) | Intergroupe Francophone de Cancerologie Thoracique | 2002-03-01 |